Literature DB >> 22664147

Epigenetic biomarkers: A new perspective in laboratory diagnostics.

J L García-Giménez1, F Sanchis-Gomar, G Lippi, S Mena, D Ivars, M C Gomez-Cabrera, J Viña, F V Pallardó.   

Abstract

Epigenetics comprises the study of chemical modifications in the DNA and histones that regulates the gene expression or cellular phenotype. However, during the last decade this term has evolved after the elucidation of different mechanisms (microRNAs and nuclear organization of the chromosomes) involved in regulating gene expression. Epigenetics and the new designed technologies capable to analyze epigenetic changes (e.g., methylated DNA, miRNAs expression, post-translational modifications on histones among others) have disclosed an appealing scenario that will offer for the biomedical sciences new biomarkers for the study of neurodegenerative diseases, multifactorial complex diseases, rare diseases and cancer. Moreover, new technologies adapted for epigenetic studies will offer promising applications that in the next years will be common technologies in clinical laboratories. In this review we discuss epigenetic modifications used as possible biomarkers in several diseases. We also present the potential of methodologies to purify histones, and high throughput technologies as candidates to be set in clinical laboratories for their high potential analyzing epigenetic processes.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22664147     DOI: 10.1016/j.cca.2012.05.021

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  17 in total

1.  Physical exercise and epigenetic modulation: elucidating intricate mechanisms.

Authors:  Helios Pareja-Galeano; Fabian Sanchis-Gomar; José Luis García-Giménez
Journal:  Sports Med       Date:  2014-04       Impact factor: 11.136

2.  Inappropriateness in laboratory medicine: an elephant in the room?

Authors:  Giuseppe Lippi; Chiara Bovo; Marcello Ciaccio
Journal:  Ann Transl Med       Date:  2017-02

Review 3.  Uncovering epigenetic landscape: a new path for biomarkers identification and drug development.

Authors:  Daiane Teixeira de Oliveira; Renata Guerra-Sá
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

Review 4.  Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.

Authors:  Ying Wang; Zhaofei Yang; Weidong Le
Journal:  Neurosci Bull       Date:  2017-07-31       Impact factor: 5.203

5.  Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.

Authors:  Melanie Spitzwieser; Elisabeth Holzweber; Georg Pfeiler; Stefan Hacker; Margit Cichna-Markl
Journal:  Breast Cancer Res       Date:  2015-09-14       Impact factor: 6.466

Review 6.  Aberrant methylation patterns in cancer: a clinical view.

Authors:  Alja Videtic Paska; Petra Hudler
Journal:  Biochem Med (Zagreb)       Date:  2015-06-05       Impact factor: 2.313

7.  Analysis of alternative splicing events for cancer diagnosis using a multiplexing nanophotonic biosensor.

Authors:  César S Huertas; Santos Domínguez-Zotes; Laura M Lechuga
Journal:  Sci Rep       Date:  2017-01-25       Impact factor: 4.379

8.  Circulating miRNAs as diagnostic biomarkers for adolescent idiopathic scoliosis.

Authors:  José Luis García-Giménez; Pedro Antonio Rubio-Belmar; Lorena Peiró-Chova; David Hervás; Daymé González-Rodríguez; José Santiago Ibañez-Cabellos; Paloma Bas-Hermida; Salvador Mena-Mollá; Eva María García-López; Federico V Pallardó; Teresa Bas
Journal:  Sci Rep       Date:  2018-02-08       Impact factor: 4.379

9.  Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients.

Authors:  Melanie Spitzwieser; Elisabeth Entfellner; Bettina Werner; Walter Pulverer; Georg Pfeiler; Stefan Hacker; Margit Cichna-Markl
Journal:  BMC Cancer       Date:  2017-04-12       Impact factor: 4.430

10.  Investigation into the promoter DNA methylation of three genes (CAMK1D, CRY2 and CALM2) in the peripheral blood of patients with type 2 diabetes.

Authors:  Jia Cheng; Linlin Tang; Qingxiao Hong; Huadan Ye; Xuting Xu; Leiting Xu; Shizhong Bu; Qinwen Wang; Dongjun Dai; Danjie Jiang; Shiwei Duan
Journal:  Exp Ther Med       Date:  2014-06-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.